Individually responsive with intelligent air

---

Lumis introduces IntelligentAir: a collection of ResMed technologies – iVAPS, iBR, AutoEPAP, Vsync, TiControl™, and Trigger and cycle – that can tailor therapy to individual breathing needs. Automatically adapting to changes during the night and at different stages of a patients’ condition, IntelligentAir makes personalised ventilation possible.

---

Intelligent Volume-Assured Pressure Support (iVAPS): maintains ventilation target*
To deliver the right volume of air for each patient’s therapy needs, iVAPS intelligently learns their unique alveolar ventilation, sets appropriate targets, then provides smooth pressure support to suit.
Intelligent Backup Rate (iBR): allows spontaneous breathing
To give patients maximum opportunity to spontaneously trigger the ventilator, iBR stays out of the way until needed. It then provides backup breaths to comfortably bring patients back to their target rate. (iBR is available in iVAPS and ST modes).
AutoEPAP: addresses obstructions and maintains upper airway patency
Responding according to the severity of the event, AitoEPAP auto-adjusts the expiratory pressure in response to partial and full obstructions. It also works to prevent events from occurring throught the night. (AutoEPAP is available in iVAPS mode).
iVAPS with iBR and AutoEPAP continuously monitor ventilation and the upper airway, and automatically adjust the therapy delivered to simplify titration and treat patients with challenging conditions. With major therapy parameters set, you can then easily fine-tune settings on a ‘per patient’ basis, so that the ventilation delivered is truly personalised for efficacy and comfort.

Provide excellent patient ventilator synchrony, even in the presence of significant leak
Set min and max limits on either side of the patient’s ideal inspiratory time to encourage spontaneous breathing.
Optimise settings according to the patient’s condition, using five trigger and cycle sensitivity levels.
For more information, contact a ResMed Business Manager on 1300 305 705. See ResMed.com/Lumis for details.
*iVAPS efficacy and tolerability have been established in nine publications across chronic obstructive pulmonary disease (CPOD) and neuromuscular disease (NMD).